{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:46:10Z","timestamp":1780411570950,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA044201"],"award-info":[{"award-number":["R01DA044201"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA044201"],"award-info":[{"award-number":["R01DA044201"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11606-021-07094-9","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T17:09:01Z","timestamp":1629220141000},"page":"769-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5747-0538","authenticated-orcid":false,"given":"Alene","family":"Kennedy-Hendricks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa B.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiden A.","family":"Huskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Meiselbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen L.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"7094_CR1","doi-asserted-by":"publisher","DOI":"10.17226\/25310","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences Engineering and Medicine","year":"2019","unstructured":"National Academies of Sciences Engineering and Medicine. Medications for Opioid Use Disorder Save Lives. Washington: The National Academies Press; 2019. doi:https:\/\/doi.org\/10.17226\/25310"},{"issue":"2","key":"7094_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","volume":"23","author":"HS Connery","year":"2015","unstructured":"Connery HS. Medication-Assisted Treatment of Opioid Use Disorder. Harv Rev Psychiatry. 2015;23(2):63-75. doi:https:\/\/doi.org\/10.1097\/HRP.0000000000000075","journal-title":"Harv Rev Psychiatry."},{"issue":"2","key":"7094_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1176\/APPI.AJP.2019.19121245","volume":"177","author":"HS Connery","year":"2020","unstructured":"Connery HS, Weiss RD. Discontinuing buprenorphine treatment of opioid use disorder: What do we (not) know? Am J Psychiatry. 2020;177(2):104-106. doi:https:\/\/doi.org\/10.1176\/APPI.AJP.2019.19121245","journal-title":"Am J Psychiatry."},{"issue":"2","key":"7094_CR4","doi-asserted-by":"publisher","first-page":"CD002207","DOI":"10.1002\/14651858.CD002207.pub4","volume":"6","author":"R Mattick","year":"2014","unstructured":"Mattick R, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014 6(2):CD002207. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"7094_CR5","doi-asserted-by":"publisher","first-page":"CD002209","DOI":"10.1002\/14651858.CD002209.pub2","volume":"3","author":"RP Mattick","year":"2009","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209. doi:https:\/\/doi.org\/10.1002\/14651858.CD002209.pub2","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"7094_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","volume":"103","author":"RP Schwartz","year":"2013","unstructured":"Schwartz RP, Gryczynsi J, O\u2019Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Heal. 2013;103(5):917-922.","journal-title":"Am J Public Heal."},{"issue":"2","key":"7094_CR7","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw open. 2020;3(2):e1920622. doi:https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622","journal-title":"JAMA Netw open."},{"issue":"3","key":"7094_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Ann Intern Med. 2018;169(3):137-145. doi:https:\/\/doi.org\/10.7326\/M17-3107","journal-title":"Ann Intern Med."},{"key":"7094_CR9","doi-asserted-by":"crossref","unstructured":"Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115(9).","DOI":"10.1111\/add.14991"},{"issue":"2","key":"7094_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","volume":"177","author":"AR Williams","year":"2020","unstructured":"Williams AR, Samples H, Crystal S, Olfson M. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder. Am J Psychiatry. 2020;177(2):117-124. doi:https:\/\/doi.org\/10.1176\/appi.ajp.2019.19060612","journal-title":"Am J Psychiatry."},{"issue":"5","key":"7094_CR11","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/add.13270","volume":"111","author":"WH Lo-Ciganic","year":"2016","unstructured":"Lo-Ciganic WH, Gellad WF, Gordon AJ, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111(5):892-902. doi:https:\/\/doi.org\/10.1111\/add.13270","journal-title":"Addiction."},{"issue":"5","key":"7094_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","volume":"39","author":"H Samples","year":"2020","unstructured":"Samples H, Williams AR, Crystal S, Olfson M. Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid. Health Aff (Millwood). 2020;39(5):747-755. doi:https:\/\/doi.org\/10.1377\/hlthaff.2019.01085","journal-title":"Health Aff (Millwood)."},{"key":"7094_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/sar.s150253","volume":"9","author":"N Ronquest","year":"2018","unstructured":"Ronquest N, Willson T, Montejano L, Nadipelli V, Wollschlaeger B. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018;Volume 9:59-78. doi:https:\/\/doi.org\/10.2147\/sar.s150253","journal-title":"Subst Abuse Rehabil."},{"key":"7094_CR14","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi:https:\/\/doi.org\/10.1136\/bmj.j1550","journal-title":"BMJ."},{"issue":"12","key":"7094_CR15","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","volume":"174","author":"DA Fiellin","year":"2014","unstructured":"Fiellin DA, Schottenfeld R, Cutter C, Moore B, Barry D, O\u2019Connor P. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947-1954.","journal-title":"JAMA Intern Med."},{"key":"7094_CR16","unstructured":"Kaiser Family Foundation. 2020 Employer Health Benefits Survey. https:\/\/www.kff.org\/health-costs\/report\/2020-employer-health-benefits-survey\/. Published 2020. Accessed October 9, 2020."},{"issue":"September","key":"7094_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","volume":"95","author":"H Samples","year":"2018","unstructured":"Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95(September):9-17. doi:https:\/\/doi.org\/10.1016\/j.jsat.2018.09.001","journal-title":"J Subst Abuse Treat."},{"issue":"11","key":"7094_CR18","doi-asserted-by":"publisher","first-page":"e004632","DOI":"10.1161\/CIRCOUTCOMES.118.004632","volume":"11","author":"J Lewey","year":"2018","unstructured":"Lewey J, Gagne JJ, Franklin J, Lauffenburger JC, Brill G, Choudhry NK. Impact of High Deductible Health Plans on Cardiovascular Medication Adherence and Health Disparities. Circ Cardiovasc Qual Outcomes. 2018;11(11):e004632. doi:https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.118.004632","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"5","key":"7094_CR19","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/j.1475-6773.2011.01252.x","volume":"46","author":"SK Reiss","year":"2011","unstructured":"Reiss SK, Ross-Degnan D, Zhang F, Soumerai SB, Zaslavsky AM, Wharam JF. Effect of switching to a high-deductible health plan on use of chronic medications. Health Serv Res. 2011;46(5):1382-1401. doi:https:\/\/doi.org\/10.1111\/j.1475-6773.2011.01252.x","journal-title":"Health Serv Res."},{"issue":"11","key":"7094_CR20","doi-asserted-by":"publisher","first-page":"e1914372","DOI":"10.1001\/jamanetworkopen.2019.14372","volume":"2","author":"AM Fendrick","year":"2019","unstructured":"Fendrick AM, Buxbaum JD, Tang Y, et al. Association Between Switching to a High-Deductible Health Plan and Discontinuation of Type 2 Diabetes Treatment. JAMA Netw open. 2019;2(11):e1914372. doi:https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.14372","journal-title":"JAMA Netw open."},{"issue":"6","key":"7094_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.37765\/ajmc.2020.43487","volume":"26","author":"J Frank Wharam","year":"2020","unstructured":"Frank Wharam J, Busch AB, Madden J, et al. Effect of high-deductible insurance on health care use in bipolar disorder. Am J Manag Care. 2020;26(6):248-255. https:\/\/doi.org\/10.37765\/ajmc.2020.43487","journal-title":"Am J Manag Care"},{"issue":"8","key":"7094_CR22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.4088\/JCP.12m08156","volume":"77","author":"MD Eisenberg","year":"2020","unstructured":"Eisenberg MD, Du S, Sen AP, Kennedy-Hendricks A, Barry CL. Health Care Spending by EnrolleesWith Substance Use and Mental Health Disorders in High-Deductible Health Plans vs Traditional Plans. JAMA Psychiatry. 2020;77(8):872-875. doi:https:\/\/doi.org\/10.4088\/JCP.12m08156","journal-title":"JAMA Psychiatry."},{"key":"7094_CR23","unstructured":"Eisenberg MD, Kennedy-Hendricks A, Schilling CJ, Busch AB, Huskamp HA, Stuart EA, Meiselbach M, Barry CL. The impact of high deductible health plans on service use and spending for substance use disorders. Under review"},{"issue":"2","key":"7094_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/02791072.2017.1300360.Commercial","volume":"49","author":"S Reif","year":"2017","unstructured":"Reif S, Creedon TB, Horgan CM, Stewart MT, Garnick DW. Commercial Health Plan Coverage of Selected Treatments for Opioid Use Disorders from 2003 to 2014. J Psychoactive Drugs. 2017;49(2):102-110. doi:https:\/\/doi.org\/10.1080\/02791072.2017.1300360.Commercial","journal-title":"J Psychoactive Drugs."},{"key":"7094_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jsat.2016.03.001","volume":"66","author":"S Reif","year":"2016","unstructured":"Reif S, Horgan CM, Hodgkin D, Matteucci AM, Creedon TB, Stewart MT. Access to Addiction Pharmacotherapy in Private Health Plans. J Subst Abuse Treat. 2016;66:23-29. doi:https:\/\/doi.org\/10.1016\/j.jsat.2016.03.001","journal-title":"J Subst Abuse Treat."},{"issue":"3","key":"7094_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1176\/appi.ps.201900373","volume":"71","author":"D Polsky","year":"2020","unstructured":"Polsky D, Arsenault S, Azocar F. Private coverage of methadone in outpatient treatment programs. Psychiatr Serv. 2020;71(3):303-306. doi:https:\/\/doi.org\/10.1176\/appi.ps.201900373","journal-title":"Psychiatr Serv."},{"issue":"May","key":"7094_CR27","doi-asserted-by":"publisher","first-page":"108040","DOI":"10.1016\/j.jsat.2020.108040","volume":"115","author":"AB Busch","year":"2020","unstructured":"Busch AB, Greenfield SF, Reif S, Normand SLT, Huskamp HA. Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment. J Subst Abuse Treat. 2020;115(May):108040. doi:https:\/\/doi.org\/10.1016\/j.jsat.2020.108040","journal-title":"J Subst Abuse Treat."},{"issue":"1","key":"7094_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/1475-6773.13223","volume":"55","author":"S Abdus","year":"2020","unstructured":"Abdus S. The role of plan choice in health care utilization of high-deductible plan enrollees. Heal Serv Res. 2020;55(1):119-127.","journal-title":"Heal Serv Res."},{"issue":"2","key":"7094_CR29","doi-asserted-by":"publisher","first-page":"e56154","DOI":"10.1371\/journal.pone.0056154","volume":"8","author":"J Kullgren","year":"2013","unstructured":"Kullgren J, Volpp K, Polsky D. Are the healthy behaviors of US high-deductible health plan enrollees driven by people who chose these plans? Smoking as a case study. PLoS One. 2013;8(2):e56154.","journal-title":"PLoS One."},{"issue":"6","key":"7094_CR30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/ajad.12553","volume":"26","author":"A Manhapra","year":"2017","unstructured":"Manhapra A, Petrakis I, Rosenheck R. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. Am J Addict. 2017;26(6):572-580. doi:https:\/\/doi.org\/10.1111\/ajad.12553","journal-title":"Am J Addict."},{"issue":"March","key":"7094_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jsat.2019.07.010","volume":"105","author":"A Meinhofer","year":"2019","unstructured":"Meinhofer A, Williams AR, Johnson P, Schackman BR, Bao Y. Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events? J Subst Abuse Treat. 2019;105(March):37-43. doi:https:\/\/doi.org\/10.1016\/j.jsat.2019.07.010","journal-title":"J Subst Abuse Treat."},{"issue":"5","key":"7094_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3810\/pgm.2014.09.2805","volume":"126","author":"A Khemiri","year":"2014","unstructured":"Khemiri A, Kharitonova E, Zah V, Ruby J, Toumi M. Analysis of buprenorphine\/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: A retrospective study of US public and private health care claims. Postgrad Med. 2014;126(5):113-120. doi:https:\/\/doi.org\/10.3810\/pgm.2014.09.2805","journal-title":"Postgrad Med."},{"key":"7094_CR33","unstructured":"Centers for Medicare & Medicaid Services. CMS Chronic Conditions Data Warehouse. www2.ccwdata.org. Published 2020. Accessed February 1, 2020."},{"issue":"28","key":"7094_CR34","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661-3679. doi:https:\/\/doi.org\/10.1002\/sim.6607","journal-title":"Stat Med."},{"issue":"1","key":"7094_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1536867X1501500102","volume":"15","author":"F Belotti","year":"2015","unstructured":"Belotti F, Deb P, Manning WG, Norton EC. twopm: Two-part models. Stata J. 2015;15(1):3-20. The Stata Journal","journal-title":"Stata J"},{"key":"7094_CR36","unstructured":"StataCorp. Stata Statistical Software: Release 16. 2019."},{"issue":"8","key":"7094_CR37","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1176\/appi.ajp.2016.16070792.The","volume":"174","author":"KM Carroll","year":"2017","unstructured":"Carroll KM, Weiss RD. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders. Am J Psychiatry. 2017;174(8):738-747. doi:https:\/\/doi.org\/10.1176\/appi.ajp.2016.16070792.The","journal-title":"Am J Psychiatry."},{"issue":"7","key":"7094_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/MLR.0000000000000727","volume":"55","author":"B Saloner","year":"2017","unstructured":"Saloner B, Daubresse M, Alexander GC. Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population. Med Care. 2017;55(7):669-676. doi:https:\/\/doi.org\/10.1097\/MLR.0000000000000727","journal-title":"Med Care."},{"key":"7094_CR39","doi-asserted-by":"publisher","unstructured":"Anderson KE, Saloner B, Eckstein J, et al. Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder. Med Care. 2021;Publish Ah(5):393-401. https:\/\/doi.org\/10.1097\/mlr.0000000000001530","DOI":"10.1097\/mlr.0000000000001530"},{"issue":"May","key":"7094_CR40","doi-asserted-by":"publisher","first-page":"108062","DOI":"10.1016\/j.jsat.2020.108062","volume":"116","author":"TL Mark","year":"2020","unstructured":"Mark TL, Hinde JM, Zarkin GA, Parish W, Kluckman M. Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance. J Subst Abuse Treat. 2020;116(May):108062. doi:https:\/\/doi.org\/10.1016\/j.jsat.2020.108062","journal-title":"J Subst Abuse Treat."},{"issue":"8","key":"7094_CR41","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1176\/appi.ps.201900309","volume":"71","author":"E Agbese","year":"2020","unstructured":"Agbese E, Leslie DL, Manhapra A, Rosenheck R. Early discontinuation of buprenorphine therapy for opioid use disorder among privately insured adults. Psychiatr Serv. 2020;71(8):779-788. doi:https:\/\/doi.org\/10.1176\/appi.ps.201900309","journal-title":"Psychiatr Serv."},{"issue":"7","key":"7094_CR42","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1176\/appi.ps.201700363","volume":"69","author":"A Manhapra","year":"2018","unstructured":"Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatr Serv. 2018;69(7):768-776. doi:https:\/\/doi.org\/10.1176\/appi.ps.201700363","journal-title":"Psychiatr Serv."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-021-07094-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-021-07094-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-021-07094-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:06:53Z","timestamp":1660694813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-021-07094-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["7094"],"URL":"https:\/\/doi.org\/10.1007\/s11606-021-07094-9","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"17 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}